QP29-16 Implementation of New Utilization Management Platform

P2-17 Updated: Change in Coverage for Detoxification Services for Minnesota Health Care Programs Subscribers

Hepatitis C Direct Acting Antivirals - Medicaid

Prior Authorization, Quantity Limit

IBS-D (Lotronex, Viberzi) - Medicaid

Prior Authorization, Quantity Limit

Peginterferon and Ribavirin - Medicaid

Prior Authorization

Xolremdi (mavorixafor) - Commercial

Prior Authorization, Quantity Limit

Xolremdi (mavorixafor) - Medicaid

Prior Authorization, Quantity Limit

Journavx - Commercial

Quantity Limit

Journavx - Medicaid

Quantity Limit

Wakix (pitolisant) - Commercial

Prior Authorization, Quantity Limit